A number of observations have described sensitivity of AR-resistant prostate cancer cells to death induced by certain triggers such as TWEAK, sorafenib, olaparib, and inhibition of BET proteins or PLK1, among others75,95,99,102,104. Here, PLK1 is linked to prostate carcinoma.